Accuracy of the Truenat MTB-RIF Dx assay for detection of rifampicin resistance-associated mutations - 11/03/21
Doi : 10.1016/j.tube.2021.102064
Narayanan Sivaramakrishnan Gomathi, Priya Rajendran, V. Nagalakshmi
Indian Council for Medical Research-National Institute for Research in Tuberculosis, Chennai, India
M. Michel Prem Kumar
Indian Council for Medical Research-National Institute for Research in Tuberculosis, Chennai, India
Srikanth Tripathy
Indian Council for Medical Research-National Institute for Research in Tuberculosis, Chennai, India
Morten Ruhwald, Samuel G. Schumacher, Adam Penn-Nicholson ⁎ 
Foundation for Innovative New Diagnostics, Geneva, Switzerland
∗Corresponding author. FIND, Campus Biotech, Chemin des Mines 9, 1202, Geneva, Switzerland.FINDCampus BiotechChemin des Mines 9Geneva1202Switzerland
Keywords : Diagnostics, Rifampicin resistance, Point-of-care, Tuberculosis, Analytical
Le texte complet de cet article est disponible en PDF.
Plan
© 2021
Elsevier Ltd. Tous droits réservés.
Vol 127
Article 102064- mars 2021 Retour au numéro
Article précédent
- Point-of-care detection of tuberculosis using magnetoresistive biosensing chip
- Shagun Gupta, Purva Bhatter, Vipan Kakkar
- HDAC3 inhibitor RGFP966 controls bacterial growth and modulates macrophage signaling during Mycobacterium tuberculosis infection
- Monica Campo, Sarah Heater, Glenna J. Peterson, Jason D. Simmons, Shawn J. Skerrett, Harriet Mayanja-Kizza, Catherine M. Stein, W. Henry Boom, Thomas R. Hawn
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?